Richter Signs Agreement With Mithra on Sales of Donesta
Image by gedeonrichter.com
Hungarian pharmaceutical company Gedeon Richter on Wednesday said it signed a license agreement with Belgian peer Mithra for the commercialization of Donesta, an estetrol-based product candidate for the treatment of post-menopausal symptoms, according to a report by state news wire MTI.
The agreement extends to geographical Europe, the CIS, Latin America, Australia, and New Zealand.
Under the terms of the agreement, Mithra is eligible to receive upfront payments totaling EUR 55 million, of which EUR 5 mln was paid upon signature of a binding term sheet in December 2022, as well as EUR 15 mln in additional milestone payments subject to regulatory achievements and "tiered low double-digit" royalties depending on net sales of the 20-year term contract.
Richter will be in charge of the production and supply of Donesta for all of its territories.
Mithra announced positive top-line results from Donesta phase 3 studies in menopausal women in January 2022.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.